Last updated: February 5, 2026
OFEV (Nintedanib) is a prescription drug used to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Its supply chain comprises primary manufacturing companies, contract manufacturers, and distribution partners.
Primary Manufacturer of OFEV
Boehringer Ingelheim is the sole global manufacturer of OFEV (Nintedanib). The company developed and commercialized the drug after acquiring rights from other entities in the late 2000s. It has a dedicated manufacturing facility for Nintedanib, located primarily in Germany.
- Manufacturing sites: The key plant is in Biberach, Germany. This site produces active pharmaceutical ingredients (APIs) and finished drug products.
- Supply chain control: Boehringer Ingelheim controls the entire process from synthesis of APIs to formulation and packaging.
Contract Manufacturing Organizations (CMOs)
While Boehringer Ingelheim is the primary producer, it partners with CMOs for scale-up, fill-finish, and distribution logistics. These include:
- Patheon (Thermo Fisher Scientific): A global CMO involved in drug formulation and packaging.
- Samsung BioLogics: Engaged in large-scale API production to meet global demand.
- Registration with regulatory bodies ensures quality compliance across manufacturing.
API Suppliers
The active pharmaceutical ingredient (API) for Nintedanib is produced predominantly in:
- Germany: Boehringer Ingelheim's own facilities.
- South Korea: Samsung BioLogics supplies the API for some markets, fulfilling increasing demand.
- Other regions: Smaller or regional API manufacturers may have limited roles, but their identities are typically undisclosed due to proprietary agreements.
Distribution Channels
Distribution of OFEV primarily involves:
- Wholesalers: Major pharmaceutical distributors such as McKesson and Cardinal Health ensure supply to clinics and hospitals.
- Direct supply agreements: Boehringer Ingelheim directly supplies certain markets, especially in Europe and North America.
- Generic manufacturers: As patents expire, generic versions may emerge, with secondary suppliers entering the market, though currently, OFEV remains under patent protections globally.
Key Supply Chain Considerations
- Patent status: Patents held by Boehringer Ingelheim protect the exclusive supply of Nintedanib until approximately 2031.
- Supply chain resilience: Dependence on a limited number of manufacturing sites heightens risk of disruptions, as seen during COVID-19.
- Regional manufacturing disparities: Local manufacturing varies, impacting pricing and availability worldwide.
Summary Table of OFEV Suppliers
| Category |
Key Players |
Locations |
Scope |
| Primary Manufacturer |
Boehringer Ingelheim |
Germany |
API synthesis, formulation, packaging |
| Contract Manufacturers (CMOs) |
Patheon, Samsung BioLogics |
USA, South Korea |
Formulation, fill-finish |
| API Suppliers |
Boehringer Ingelheim, Samsung BioLogics |
Germany, South Korea |
API production |
| Distribution |
McKesson, Cardinal Health |
Global |
Wholesale distribution |
Key Takeaways
- Boehringer Ingelheim holds exclusive rights to OFEV production.
- The company manages manufacturing in Germany and partners with CMOs globally.
- API production is concentrated among Boehringer's facilities and Samsung BioLogics.
- Supply chain resilience depends on few key manufacturing sites and regional variation.
- Patent expiry around 2031 may lead to new suppliers or generic versions.
FAQs
1. Are there alternative suppliers for OFEV's API?
Currently, no; Boehringer Ingelheim and Samsung BioLogics are the primary API producers. Alternative suppliers exist but are limited and typically not involved in authorized supply.
2. How does patent protection impact supply diversification?
Patent exclusivity prevents generic manufacturing until approximately 2031, maintaining reliance on the original manufacturer's supply chain.
3. What risks threaten OFEV's supply chain?
Manufacturing disruptions at key sites, geopolitical issues, regulatory delays, or supply chain constraints for raw materials could impact availability.
4. Are there regional differences in OFEV supply?
Yes. While Europe and North America are directly supplied by Boehringer Ingelheim, other regions may rely on regional distributors or pending generic entries post-patent expiry.
5. Will new suppliers enter the OFEV market post-patent?
Likely. Patent expiration will enable generic manufacturers to produce Nintedanib, increasing supply options and potentially reducing costs.
Sources:
- Boehringer Ingelheim official site. "OFEV (Nintedanib) Overview."
- U.S. FDA Drug Approval Database.
- Patent expiration data: www.lawinsider.com.
- Contract manufacturing disclosures from Therapeutic Monograph Reports.
- Industry reports on API manufacturing hubs.
